Devonyu
Neurocrine Biosciences (NASDAQ:NBIX) has halted development of luvadaxistat as a result of disappointing outcomes from a Phase 2 study of the drug within the remedy of cognitive impairment in schizophrenia sufferers.
The firm mentioned the study failed to fulfill its main endpoint or replicate the cognitive endpoints information seen in an earlier study known as INTERACT, in response to an announcement.
Neurocrine attributed the study failure partly to “the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms.”
Rather than pursuing additional development of the drug, Neurocrine plans to concentrate on advancing NBI-1117568 for schizophrenia and NBI-1065845 for main depressive dysfunction into Phase 3 testing.
In late August, Neurocrine reported optimistic Phase 2 information for NBI-1117568, which it mentioned supported development of the drug into Phase 3 trials in early 2025.
More on Neurocrine Biosciences
Source: Seekingalpha